Comparing two medicines for psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This trial compares two medicines for people with psoriatic arthritis who still have joint, skin, or nail symptoms after methotrexate. One medicine is apremilast (a pill), and the other is adalimumab (an injection). The study aims to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have psoriatic arthritis that mainly affects your joints, tendons, or fingers/toes (peripheral symptoms).
- You have taken methotrexate for at least 3 months and it hasn't worked well enough.
- You have not received biologic treatments (like adalimumab) or JAK inhibitor pills before.
- You do not have active infections like tuberculosis or hepatitis B or C, no recent cancer, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
This study compares two “treat-to-target” strategies for psoriatic arthritis. One strategy uses imaging to guide treatment changes, and the other uses standard clinic assessments, to see which approach controls symptoms more effectively.
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
This study compares two oral medications, methotrexate and apremilast, to see which works better at reducing itching in people with psoriasis. You might join to help find a more effective way to relieve itch.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
This trial tests if a treatment can prevent joint damage in people recently diagnosed with psoriatic arthritis. It compares a standard medication (methotrexate) with or without a newer biologic drug (adalimumab) to see which is better at stopping the disease from causing lasting harm.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.